NCT03027336View on ClinicalTrials.gov

Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

October 31, 2016

Conditions
Dyslipidemias
Interventions
DIETARY_SUPPLEMENT

Coleosoma

patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.

DIETARY_SUPPLEMENT

Placebo

patients will take one tablet daily for 12 weeks.

Trial Locations (1)

43126

Endocrinology Unit, Parma

All Listed Sponsors
collaborator

DOC generici srl

UNKNOWN

lead

Azienda Ospedaliero-Universitaria di Parma

OTHER

NCT03027336 - Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects | Biotech Hunter | Biotech Hunter